# Claus A. Andersson

> Claus A. Andersson is a Series A investor at Sunstone Life Science Ventures backing Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science)
- Location: Copenhagen, Denmark
- Total investments: 5
- Last investment: Jan 2024
- Lead investor: 80%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/clausandersson
- Website: https://sunstone.eu/team-members/claus-andersson/

Claus A. Andersson is a Series A investor at Sunstone Life Science Ventures in Copenhagen focused on Biotechnology and Medical. Claus Andersson is General Partner in Sunstone Life Sciences Ventures. He has over 16 years of industrial experience and more than 12 years of dedicated venture capital experience in the biotechnology industry.Claus Andersson holds a PhD in multivariate statistics, which he obtained at the University of Copenhagen and the Humboldt University,Berlin, and a Master of Science in Civil Engineering in Chemistry.He has published 17 peer reviewed scientific publications in biology and mathematics, and has served as editorial board member in 3 scientific journals.While obtaining his PhD, Claus Andersson served as manager in Radiometer Medical A/S which he left in 2001 to start a company and has subsequently founded and co-founded three additional companies and an ICT venture fund.Claus Andersson has served on numerous boards and an updated list can be found on LinkedIn.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 40% |
| Medical | 1 | 20% |
| Health Care | 1 | 20% |
| Life Science | 1 | 20% |
| Therapeutics | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 60% |
| Series B | 1 | 20% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Italy | 1 | 20% |
| France | 1 | 20% |
| Belgium | 1 | 20% |
| Finland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Resalis Therapeutics | Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche | $10.9M | Series A | Jan 04, 2024 |  |
| DiogenX | DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes. | $36.8M | Series A | May 10, 2023 |  |
| Rewind Therapeutics | Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. |  | Series B | Jan 25, 2023 |  |
| Rewind Therapeutics | Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. |  | Series A | Jan 25, 2023 |  |
| Forendo Pharma | Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases. The company's drugs are competent in tissue-specific hormone mechanisms for the treatment of broader gynecological conditions and Fispemifene, a novel SERM, enabling medical companies to improve the treatment of maleurological conditions and giving new opportunities to unmet needs in women's and men's health. | $5.5M |  | Jul 18, 2019 |  |

5 of 5 investments shown.

## Co-investors
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 3 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 3 deals together
- [Centre for Drug Design & Discovery (CD3)](https://shizune.co/investors/profile/centre-for-drug-design-discovery-cd3) — VC Fund, 2 deals together
- [Gemma Frisius Fund](https://shizune.co/investors/profile/gemma-frisius-fund) — VC Fund, 2 deals together
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund, 2 deals together
- [AdBio partners](https://shizune.co/investors/profile/advent-france-biotechnology) — VC Fund, 1 deal together

## About Sunstone Life Science Ventures

VC Fund · Copenhagen, Denmark

Sunstone Life Science Ventures is a European, early-stage VC investing in novel pharmaceutical ingredients for human therapeutic use

5 contacts available at Sunstone Life Science Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Claus A. Andersson | General Partner | https://shizune.co/investors/profile/claus-andersson |
| Jacob Lange Moresco | Investment Director | https://shizune.co/investors/profile/jacob-lange-moresco |
| Line Jacobsen | Management Assistant | https://shizune.co/investors/profile/line-jacobsen |
| Peter Benson | Chairman and Managing Partner | https://shizune.co/investors/profile/peter-benson |
| Sten Verland | Co-Founder & General Partner | https://shizune.co/investors/profile/sten-verland |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Claus A. Andersson invest in?

Claus A. Andersson invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Claus A. Andersson last invest?

The most recent investment recorded for Claus A. Andersson closed in Jan 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co